Priaxon, utilizing its proprietory PriaXplore® platform for small molecule drug discovery, and Boehringer Ingelheim will prolongate their research and development collaboration on mdm2/p53 inhibitors for the treatment of cancer.
The companies will continue working jointly to identify and advance drug candidates into pre-clinical development.
Thereafter, Boehringer Ingelheim will drive the development and commercialization of the potential cancer treatments arising from the collaboration.
"Priaxon has been able to develop promising mdm2/p53 inhibitors with its PriaXplore® technology", said Dr Juergen Kolb, CEO of Priaxon.
Dr Kolb continued, "We are proud that Boehringer Ingelheim appreciates Priaxon as a competent partner by prolongating the collaboration to advance the high potency lead compounds. We enjoy the fair and creative atmosphere of this cooperation very much."
Priaxon is entitled to up to EUR 86 million in milestone payments upon achievement of certain development, regulatory and commercial milestones as well as royalties on potential future net sales of products.